Join the Kanjinti group to help and get support from people like you.
Kanjinti News
Adjuvant Trastuzumab Emtansine Improves Overall Survival in HER2+ Breast Cancer
THURSDAY, Jan. 16, 2025 – For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab emtansine (T-DM1) improves overall survival more than...
FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin
THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ – Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Kanjinti...
Further information
Related condition support groups
Breast Cancer - Adjuvant, Breast Cancer, Breast Cancer, Metastatic, Gastric Cancer